channel 7 parkinson, page-19

LCT will have no access to any data related to the phase 2b trial. Dr Snow and his team, as independent researchers, will have some idea how the patients are progressing based on unblinded raw data, although this certainly won't be shared with the market.

We certainly won't receive any indication specifically how the current trial is looking from an efficacy point of view. But what we do know is there are no safety concerns as the company is obligated to inform the market if an adverse events arise at any stage.

If you read back over some great comments made on this forum there is plenty that the company can do ( and hopefully are doing) between now and November in terms of setting up patient registers for the phase 3 trial, finalising a business model etc. so they are not at a standing start assuming positive phase 2b results.

Hopefully the company is able to share some of the commercial progress they have made behind the scenes assuming a positive trial outcome in their next market update.